Kezar Life Sciences (NASDAQ:KZR) Given New $11.00 Price Target at Wells Fargo & Company

Kezar Life Sciences (NASDAQ:KZR) had its target price lowered by Wells Fargo & Company from $20.00 to $11.00 in a report published on Thursday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

Other research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a research note on Monday, October 14th. William Blair reaffirmed a “market perform” rating on shares of Kezar Life Sciences in a research report on Wednesday.

Kezar Life Sciences Price Performance

NASDAQ KZR opened at $7.46 on Thursday. Kezar Life Sciences has a 52 week low of $5.20 and a 52 week high of $11.35. The company has a quick ratio of 9.58, a current ratio of 7.65 and a debt-to-equity ratio of 0.05. The company has a fifty day moving average of $7.20 and a two-hundred day moving average of $6.83.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($2.78) EPS for the quarter, topping analysts’ consensus estimates of ($3.03) by $0.25. As a group, equities analysts predict that Kezar Life Sciences will post -6.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Kezar Life Sciences

Large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd lifted its holdings in shares of Kezar Life Sciences by 256.1% in the 3rd quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock worth $40,000 after buying an additional 37,504 shares during the period. Mackenzie Financial Corp bought a new position in shares of Kezar Life Sciences during the 2nd quarter worth approximately $35,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Kezar Life Sciences during the second quarter valued at approximately $63,000. BNP Paribas Financial Markets boosted its stake in Kezar Life Sciences by 35.4% in the first quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock valued at $247,000 after acquiring an additional 71,543 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Kezar Life Sciences by 15.0% in the third quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock worth $485,000 after purchasing an additional 81,678 shares during the last quarter. 67.90% of the stock is owned by hedge funds and other institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.